Instability of miRNA and cDNAs derivatives in RNA preparations

Bravo, Valia; Rosero, Samuel; Ricordi, Camillo; Pastori, Ricardo L.

doi:10.1016/j.bbrc.2006.12.135

Cited by 61 publications

(39 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17,18 Therefore, the development of safe and efficient miRNA carriers is a prerequisite for the success of combination therapy. Currently, the combination of gene and chemical drugs can be classified into three categories: 1) chemotherapy combined with gene carrying nanoparticles; 19 2) codelivery; 20 and 3) use of multiple nanocarriers.…”

Section: Liu Et Almentioning

confidence: 99%

MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell

Li¹,

Meng²,

Yuan³

et al. 2016

IJN

View full text Add to dashboard Cite

Section: Liu Et Almentioning

confidence: 99%

MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell

Li¹,

Meng²,

Yuan³

et al. 2016

IJN

View full text Add to dashboard Cite

“…[ 11 ] These obstacles include poor stability and integrity in vivo, [ 12 ] high rate of blood clearance, risk of systemic toxicity, [ 13 ] poor intracellular delivery, and poor aggregation to the targeted tissues and cells to achieve effi cient gene silencing. [ 14 ] Both viral vectors and nonviral delivery systems can be developed to circumvent these challenges.…”

Section: Introductionmentioning

confidence: 99%

Folic‐Acid‐Mediated Functionalized Gold Nanocages for Targeted Delivery of Anti‐miR‐181b in Combination of Gene Therapy and Photothermal Therapy against Hepatocellular Carcinoma

Huang

Duan

Wang

et al. 2016

Adv Funct Materials

121

View full text Add to dashboard Cite

Therapeutic strategies based on modulation of microRNAs (miRNAs) activity hold much promise for cancer therapy, but for clinical applications, the effi cient delivery of miRNAs to tumor cells or tumor tissues remains a great challenge. In this work, microRNA-181b inhibitor (anti-miR-181b) is successfully condensed into polyethyleneimine (PEI)-modifi ed and folate receptor (FR)-targeted PEGylated gold nanocages (AuNCs). This delivery system is designated as anti-miR-181b/PTPAuNCs nanocomplexes (PTPAuNC-NPs), which begin with chemical modifi cation of AuNCs with SH-PEG 5000 -folic acid (SH-PEG 5000 -FA) and SH-PEG 5000 through a gold-sulfur bond, followed by conjugating PEI using lipoic acid as a linker. Finally anti-miR-181b is condensed via electrostatic interactions. In vitro and in vivo experiments show that PTPAuNC-NPs can effi ciently deliver anti-miR-181b into target sites to suppress tumor growth, and considerably decrease tumor volumes in SMMC-7721 tumor-bearing nude mice under near-infrared radiation. All these results suggest that PTPAuNC-NP gene delivery system with combination of gene therapy and photothermal therapy will be of great potential use in future cancer therapy.

show abstract

“…To eliminate the possibility of miRNA degradation and potential false results documented in the study by Bravo et al [19], the isolation procedure, RT and qRT-PCR reaction of samples were performed within 2 days, with the isolation procedure taking place on the 1st day.…”

Section: Methodsmentioning

confidence: 99%

MicroRNAs miR-1, miR-133a, miR-133b and miR-208 Are Dysregulated in Human Myocardial Infarction

Boštjančič

Zidar²,

Štajer³

et al. 2009

Cardiology

276

192

View full text Add to dashboard Cite

Objectives: MicroRNAs (miRNAs) are noncoding single-stranded RNA molecules that regulate gene expression in physiological functions, development and disease. In recent studies, three miRNAs have been described as muscle or cardiac specific: miR-1, miR-133, and miR-208, being involved in heart development and disease; but there are limited data on their role in human myocardial infarction (MI). We therefore analyzed their expression in human MI. Methods: Autopsy samples of infarcted heart tissue from 50 patients with MI, 8 healthy trauma victims and 9 fetuses that died in utero were included. miRNAs miR-1, miR-133a/b and miR-208 were analyzed using quantitative real-time polymerase chain reaction. Results:miR-208 was upregulated, whereas miR-1 and miR-133a were downregulated in MI compared to healthy adult and fetal hearts. All four tested miRNAs were downregulated in fetal hearts compared to healthy adult hearts. Conclusions: Our study showed the involvement of muscle- and/or cardiac-specific miRNAs miR-1, miR-133a/b and miR-208 in human MI. The most significant finding was upregulation of miR-208 and downregulation of miR-1 and miR-133a in MI compared to healthy adult hearts. Some patterns of miRNA expression were similar in MI and fetal hearts, supporting the concept of cardiac gene reprogramming in the remodeling of the heart.

show abstract

Instability of miRNA and cDNAs derivatives in RNA preparations

Cited by 61 publications

References 15 publications

MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell

MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell

Folic‐Acid‐Mediated Functionalized Gold Nanocages for Targeted Delivery of Anti‐miR‐181b in Combination of Gene Therapy and Photothermal Therapy against Hepatocellular Carcinoma

MicroRNAs<i> miR-1</i>,<i> miR-133a, miR-133b </i>and <i>miR-208</i> Are Dysregulated in Human Myocardial Infarction

Contact Info

Product

Resources

About